Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Tanic, M; Andres, E; Rodriguez-Pinilla, SM; Marquez-Rodas, I; Cebollero-Presmanes, M; Fernandez, V; Osorio, A; Benitez, J; Martinez-Delgado, B.

MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours

BRITISH JOURNAL OF CANCER. 2013; 109(10): 2724-2734 Nº de citas: 18 [doi:10.1038/bjc.2013.612]

Alvarez, YE; Sola, ABI; Rodriguez, MC; Mateos, RG; Rueda, AM; Sanchez, CAR; Mesa, DR; Rodriguez, ATI.

Diagnosis and treatment of break-through cancer pain: Consensus recommendations

Medicina Paliativa. 2013; 20(4): 150-157 [doi:10.1016/j.medipa.2013.03.005]

Casas, A; Llombart, A; Martin, M.

Denosumab for the treatment of bone metastases in advanced breast cancer

BREAST. 2013; 22(5): 585-592 Nº de citas: 23 [doi:10.1016/j.breast.2013.05.007]

Calvo, FA; Sole, CV; Lozano, MA; Gonzalez-Bayon, L; Gonzalez-Sansegundo, C; Alvarez, A; Blanco, J; Calin, A; Lizarraga, S; Garcia-Sabrido, JL.

Intraoperative electron beam radiotherapy and extended surgical resection for gynecological pelvic recurrent malignancies with and without external beam radiation therapy: Long-term outcomes

Gynecologic Oncology. 2013; 130(3): 537-544 Nº de citas: 23 [doi:10.1016/j.ygyno.2013.05.016]

Martin, M; Custodio, S; de las Casas, MLM; Garcia-Saenz, JA; de la Torre, JC; Bellon-Cano, JM; Lopez-Tarruella, S; Vidaurreta-Lazaro, M; de la Orden, V; Jerez, Y; Marquez-Rodas, I; Casado, A; Sastre, J; Diaz-Rubio, E.

Circulating Tumor Cells Following First Chemotherapy Cycle: An Early and Strong Predictor of Outcome in Patients With Metastatic Breast Cancer

ONCOLOGIST. 2013; 18(8): 917-923 Nº de citas: 35 [doi:10.1634/theoncologist.2012-0479]

Sanchez-Espiridion, B; Martin-Moreno, AM; Montalban, C; Figueroa, V; Vega, F; Younes, A; Medeiros, LJ; Alves, FJ; Canales, M; Estevez, M; Menarguez, J; Sabin, P; Ruiz-Marcellan, MC; Lopez, A; Sanchez-Godoy, P; Burgos, F; Santonja, C; Lopez, JL; Piris, MA; Garcia, JF.

MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma

BRITISH JOURNAL OF HAEMATOLOGY. 2013; 162(3): 336-347 Nº de citas: 38 [doi:10.1111/bjh.12390]

Martin, M; Ruiz, A; Borrego, MR; Barnadas, A; Gonzalez, S; Calvo, L; Vila, MM; Anton, A; Rodriguez-Lescure, A; Segui-Palmer, MA; Munoz-Mateu, M; Ribugent, JD; Lopez-Vega, JM; Jara, C; Espinosa, E; Fernandez, CM; Andres, R; Ribelles, N; Plazaola, A; Sanchez-Rovira, P; Bofill, JS; Crespo, C; Carabantes, FJ; Servitja, S; Chacon, JI; Rodriguez, CA; Hernando, B; Alvarez, I; Carrasco, E; Lluch, A.

Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study

JOURNAL OF CLINICAL ONCOLOGY. 2013; 31(20): 2593 Nº de citas: 51 [doi:10.1200/JCO.2012.46.9841]

Escobar, Y; Manas, A; Julia, J; Galvez, R; Zaragoza, F; Margarit, C; Lopez, R; Casas, A; Anton, A; Cruz, JJ.

Optimal management of breakthrough cancer pain (BCP)

Clinical & Translational Oncology. 2013; 15(7): 526-534 Nº de citas: 9 [doi:10.1007/s12094-012-0981-1]

Garrido, P; Rosell, R; Arellano, A; Andreu, F; Domine, M; Perez-Casas, A; Cardenal, F; Arnaiz, MD; Moran, T; Morera, R; Isla, D; Valencia, J; Cobo, M; Delgado, R; Garcia-Gomez, R; Calvo, F; Zamora, J; Ramos, A; Massuti, B.

Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: Mature results of the Spanish Lung Cancer Group 0008 study

LUNG CANCER. 2013; 81(1): 84-90 Nº de citas: 23 [doi:10.1016/j.lungcan.2013.03.009]

Au, HJ; Eiermann, W; Robert, NJ; Pienkowski, T; Crown, J; Martin, M; Pawlicki, M; Chan, A; Mackey, J; Glaspy, J; Pinter, T; Liu, MC; Fornander, T; Sehdev, S; Ferrero, JM; Bee, V; Santana, MJ; Miller, DP; Lalla, D; Slamon, DJ.

Health-Related Quality of Life With Adjuvant Docetaxel- and Trastuzumab-Based Regimens in Patients with Node-Positive and High-Risk Node-Negative, HER2-Positive Early Breast Cancer: Results from the BCIRG 006 Study

ONCOLOGIST. 2013; 18(7): 812-818 Nº de citas: 23 [doi:10.1634/theoncologist.2013-0091]

Alfonso, PG; Martin, AM; Suarez, SA; Codeidido, MB; Solis, RM; Rico, GT; Martin, PL; Martin, M.

Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II

ONKOLOGIE. 2013; 36(6): 363-367 Nº de citas: 4 [doi:10.1159/000351240]

Alba, E; Ciruelos, E; Lopez, R; Lopez-Vega, JM; Lluch, A; Martin, M; Munoz, M; Sanchez-Rovira, P; Segui, MA; Liria, MR; Perez-Alcantara, F.

Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain

Expert Review of Pharmacoeconomics & Outcomes Research. 2013; 13(3): 381 Nº de citas: 20 [doi:10.1586/ERP.13.18]

Amadori, D; Carrasco, E; Roesel, S; Labianca, R; Uziely, B; Soldatenkova, V; Moreau, V; Desaiah, D; Bauknecht, T; Martin, M.

A randomized phase II non-comparative study of pemetrexed-carboplatin and gemcitabine-vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients

INTERNATIONAL JOURNAL OF ONCOLOGY. 2013; 42(5): 1778-1785 Nº de citas: 8 [doi:10.3892/ijo.2013.1869]

Martin, M; Prat, A; Rodriguez-Lescure, A; Caballero, R; Ebbert, MTW; Munarriz, B; Ruiz-Borrego, M; Bastien, RRL; Crespo, C; Davis, C; Rodriguez, CA; Lopez-Vega, JM; Furio, V; Garcia, AM; Casas, M; Ellis, MJ; Berry, DA; Pitcher, BN; Harris, L; Ruiz, A; Winer, E; Hudis, C; Stijleman, IJ; Tuck, DP; Carrasco, E; Perou, CM; Bernard, PS.

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

BREAST CANCER RESEARCH AND TREATMENT. 2013; 138(2): 457-466 Nº de citas: 93 [doi:10.1007/s10549-013-2416-2]

Romero, A; Garcia-Saenz, JA; Fuentes-Ferrer, M; Garcia-Asenjo, JAL; Furio, V; Roman, JM; Moreno, A; de la Hoya, M; Diaz-Rubio, E; Martin, M; Caldes, T.

Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients

ANNALS OF ONCOLOGY. 2013; 24(3): 655-661 Nº de citas: 57 [doi:10.1093/annonc/mds493]

von Minckwitz, G; Martin, M; Wilson, G; Alba, E; Schmidt, M; Biganzoli, L; Awada, A.

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2013; 85(3): 315-331 Nº de citas: 22 [doi:10.1016/j.critrevonc.2012.09.009]

Ocana, A; Amir, E; Seruga, B; Martin, M; Pandiella, A.

The evolving landscape of protein kinases in breast cancer: Clinical implications

CANCER TREATMENT REVIEWS. 2013; 39(1): 68-76 Nº de citas: 19 [doi:10.1016/j.ctrv.2012.05.004]

Garnett, SA; Martin, M; Jerusalem, G; Petruzelka, L; Torres, R; Bondarenko, IN; Khasanov, R; Verhoeven, D; Pedrini, JL; Smirnova, I; Lichinitser, MR; Pendergrass, K; Lindemann, JPO; Di Leo, A.

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

BREAST CANCER RESEARCH AND TREATMENT. 2013; 138(1): 149-155 Nº de citas: 17 [doi:10.1007/s10549-012-2395-8]